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Abstract 
A rational design approach is proposed for a multifunctional enzyme reagent for point-of-care diagnostics. The biomaterial reduces down-
stream isolation steps and eliminates immobilization coupling chemicals for integration in a diagnostic platform. Fusion constructs combined 
the central functional assay protein (e.g. monomeric sarcosine oxidase, mSOx, horseradish peroxidase, HRP), a visualizing protein (e.g. 
mCherry) and an in-built immobilization peptide (e.g. R5). Monitoring protein expression in E.coli was facilitated by following the increase 
in mCherry fluorescence, which could be matched to a color card, indicating when good protein expression has occurred. The R5 peptide 
(SSKKSGSYSGSKGSKRRIL) provided inbuilt affinity for silica and an immobilization capability for a silica based diagnostic, without 
requiring additional chemical coupling reagents.  Silica particles extracted from beach sand were used to collect protein from crude protein 
extract with 85-95% selective uptake. The silica immobilized R5 proteins were stable for more than 2 months at room temperature. The Km 
for the silica-R52-mCh-mSOx-R5-6H was 16.5±0.9mM (compared with 16.5±0.4 mM, 16.3±0.3 mM, and 16.1±0.4 mM for R52-mCh-
mSOx-R5-6H, mSOx-R5-6H and mSOx-6H respectively in solution). The use of the “silica-enzymes” in sarcosine and peroxide assays was 
shown, and a design using particle sedimentation through the sample was examined. Using shadowgraphy and particle image velocimetry 
the particle trajectory through the sample was mapped and an hourglass design with a narrow waist shown to give good control of particle 
position. The hourglass biosensor was demonstrated for sarcosine assay in the clinically useful range of 2.5 to 10 µM in both a dynamic and 
end point measurement regime. 
 
Graphical abstract 
 
 
 
Keywords: biosensors; multifunctional protein; immobilization; protein engineering; sarcosine; silaffin; silica; resource-poor production.  
 
 
 
  
2 
1. Introduction 
It has been proposed that low cost in vitro diagnostics 
(IVD) in clinical practice can, in general, facilitate decision-
making to guide management of the patient pathway with 
improved cost effectiveness [1,2].  However, according to a 
study from Deloitte, 75% of clinical decisions are based on 
tests that have to be undertaken in a hospital pathology la-
boratory. This is too slow to influence the first response in 
patient treatment [3] and not affordable for resource poor 
countries.  
In low resource areas, the immediate need is often dis-
cussed for communicable disease, but chronic non-com-
municable diseases (CNCD), account for more than half the 
burden of disease and the greatest global share of death and 
disability, affecting people of all ages, nationalities and clas-
ses. It is estimated that two thirds of cancer cases will 
emerge in low and middle income countries (LMICs) by the 
end of the next decade [4,5]. Unfortunately, early diagnosis 
programs are not affordable in this context. Currently, IVDs 
typically only include assays like blood glucose and choles-
terol and they are especially challenging to afford and inte-
grate into LMICs [6]. 
Lack of beneficial monitoring in the management of di-
abetes for example, is one of the biggest contrasts with high 
income countries. In Mozambique only 6% of facilities 
could carry out a blood glucose analysis and personal moni-
toring is not available in general [7]. Yet, the high preva-
lence of diabetes in LMICs is not accounted for by conven-
tional risk factors including body mass index (BMI) [8] and 
an increasing number of the populations are contracting type 
2 diabetes at a younger age [9]. Monitoring is beyond their 
financial reach and is thus an impediment for surveillance 
and clinical management.  
There have been numerous attempts to propose low cost 
diagnostics for LMICs, but they remain at high cost when 
taken in the local context. Social innovation studies empha-
size the need to improve society’s capacity to solve their 
own problems [10]. Innovation is therefore required to em-
power low income countries, through local production, with-
out subsidies or major infrastructure investment [11–13]. 
However, the required biological materials for a point of 
care diagnostic can be the largest proportion of the total cost 
for the device (e.g. >80% in the Philippines, at nearly the 
same cost price as in US and Europe, despite the average 
household income being 80-90% lower).  
Pursuance of paper diagnostics [14,15] and use of other 
low cost manufacturable substrates has been studied as an 
approach to affordable medical diagnostics in limited re-
source settings [16]. The ‘plastic-free’ biodegradable move-
ment will further encourage the use of plant based materials 
and the sourcing of naturally occurring renewables (e.g. zein 
[17]) and other readily available materials. Silica is an ex-
ample of such a low cost available material that can be easily 
modified chemically, to present different external functional 
pendant groups, allowing tethering of biological molecules 
and other components [18,19]. Silica based sol-gel materials 
have provided an immobilization encapsulant [20], offering 
useful biocompatibility for biosensors, with retention of ac-
tivity of immobilized biomolecules and integration with var-
ious transduction techniques [21].  
Surface modification of the substrate is one of the key 
objectives in biosensor design to unite the biorecognition 
chemistry with the measurement system and integrate the 
core analytical reagent [22]. This could be replaced by post-
translational addition of specific peptides [23,24]. Neverthe-
less, taking a synthetic biology approach to the biorecogni-
tion reagent, suggests that a modular synthetic protein de-
sign, able to perform the tasks of both biorecognition and 
immobilization could eliminate a number of steps in the pro-
duction pathway. This could reduce the use (and cost) of 
chemical reagents and processing steps. Furthermore, such 
modular protein design allows other potentially cost saving 
or optimizing functionality to be included.  In the research 
reported herein, we propose a multiprotein-complex design, 
to achieve these aims. A fusion protein construct is explored 
that combines A) the central functional assay protein (e.g. 
enzyme); B) a visualizing protein (e.g. fluorescent protein) 
to provide a reference measurement in the final diagnostic 
and facilitating visual monitoring of the production and iso-
lation without a laboratory infrastructure; C) an in-built im-
mobilization peptide which is fundamental to stabilization 
and effective interfacing with (i) the sample (ii) the diagnos-
tic platform and importantly (iii) plays a key role in simpli-
fying isolation and purification. Depending on the choice of 
peptide, different platform substrate materials can be chosen 
(e.g. paper, silica, metals, carbon etc.). This initial study will 
focus on silica as the core low cost abundantly available ma-
terial. It takes a ‘gene to diagnostic’ approach to materials 
that can be expressed in vivo in E. coli with one step purifi-
cation and silica biosensor integration.  
In this preliminary demonstration, the enzyme sarcosine 
oxidase is explored as a first model. Sarcosine levels have 
been studied in urine as a marker of early-stage prostate can-
cer, when its level rises over 5 µM [25,26]. Interest in sarco-
sine as a biomarker for prostate cancer is stimulating ideas 
for IVDs and with access to diagnostics unaffordable in vul-
nerable LMICs, there is a need to consider a different ap-
proach that doesn’t presume the use of expensive off-the-
shelf reagents.  
Taking inspiration from “Garage Biotech”, which has 
captured the interest of the hobbyists and enabled the DIY 
scientist to produce proteins with no conventional laboratory 
resources [27], we report on the first steps to demonstrate the 
principle of  “gene to device”, short-circuiting downstream 
processing and immobilization steps and showing that the 
silica material focus can open up new directions for diagnos-
tic platform design. 
 
2. Materials and Methods 
Materials sourced from Sigma-Aldrich: sarcosine, horse 
radish peroxidase (HRP), isopropyl β-D-1-thiogalactopyra-
noside (IPTG), sodium chloride (NaCl), sodium phosphate 
dibasic (Na2HPO4), potassium phosphate monobasic 
(KH2PO4), sodium hydroxide (NaOH), lysozyme (from 
chicken egg white), TritonX-100, sulfuric acid (H2SO4 
95%), bovine serum albumin (BSA), 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS), Coomaisse 
Brilliant Blue, phosphoric acid, L-ascorbic acid, glucose, 
glycine, silica gel 150 250-500µm, benzonase nuclease, im-
idazole, 2-mercaptoethanol, calcium chloride (CaCl2). Ma-
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terials sourced from Invitrogen: Amplex UltraRed. Materi-
als sourced from Melford Laboratories: LB Agar (L1706), 
LB Broth (L1704), Kanamycin (K0126), carbenicillin. Ma-
terials source from Acros Organics: potassium chloride 
(KCl), uric acid, L-alanine, L-proline, creatinine. Materials 
sourced from alternate suppliers: commercial silica gel 60 
(<63µm/mesh <230 (Fluka), 6-35µm (Fisher Scientific), 40-
63µm (Merck), 63-210µm (YMC), 200-500µm (Macherey 
Nagel)), polymethylmethacrylate (PMMA, Engineering and 
Design Plastics), glycerol (Fisher Scientific), hydrogen per-
oxide (30%w/v in H2O, Fisher Bioreagents), dopamine salt 
(LKT laboratories Inc.), N-methyl-L-alanine (Alfa Asear), 
5-aminolevulinic acid (Cayman Chemical Company). 
 
2.1 Protein design and expression for R55-mCh-6H, R52-
mCh-mSox-R5-6H 
 
E.coli glycerol stock with mCherry-6H, mCherry-R5-
6H, and R55-mCherry-6H constructs in pET24a expression 
vector were prepared previously in house. Chemically com-
petent NovaBlue Singles E.coli cells (endA1 
hsdR17 (rK12– mK12+) supE44 thi-1 recA1 gyrA96 relA1 
lacF’[proA+B+lacIqZΔ M15::Tn10] (TetR)) were used for 
transformation and plasmid propagation. pET24a was used 
as the expression vector.  
The original mSOx sequence was ordered from Gene-
ArtTM Gene Synthesis. For mSOx, the genes were cloned 
into pET24a plasmids previously available in house. The 
pET24a vector encoding mSOx-R5 was used as a template 
for R52-mCherry-mSOx-R5 fusion protein construction. 
The vector was subjected to site directed mutagenesis aimed 
to add two restriction sites of NdeI and BamHI for insertion 
of the mSOx-R5 gene, while the stop codon was placed at 
the end of the sequence.  
 
2.2 Protein design and expression for HRP-mCh-R5-6H and 
6H-R5-mCh-HRP 
 
The HRP sequences were ordered from GeneArtTM Gene 
Synthesis. The genes were cloned into pAK plasmid. The 
constructs were assembled in NEB Turbo cells using the 
Klenow Assembly Method. PCR, transformation and DNA 
sequencing were completed as aforementioned (Supporting 
Information, Experimental). 
 
2.3 Protein purification, all constructs 
 
Protein purification was performed using Nickel His-
Bind Resin (Novagen). The purification columns were pre-
pared as recommended by the manufacturer. The column 
was first washed by 5x bed volume of equilibration buffer 
(20 mM sodium phosphate, 500 mM NaCl, 20 mM imidaz-
ole, pH 7.8), followed by loading the supernatant of the cell 
suspension. The impurities were removed by washing with 
3x bed volume of binding buffer (buffer A with 20 mM im-
idazole), 5x bed volume of wash buffer (buffer A with 50 
mM imidazole). The target protein was then eluted with 5x 
bed volume of elution buffer (buffer A with 250 mM imid-
azole). 
The purified proteins were confirmed using size analyses 
of denatured proteins on sodium dodecyl sulfate polyacryla-
mide gel electrophoresis (SDS-PAGE, 8% SDS). The pres-
ence of the R5-silaffin tag was confirmed by protein se-
quencing using LC-MS (Table S4). The yield for R55-mCh-
6H is 200mg/L culture, for R52-mCh-mSox-R5-6H is 
220mg/L, for HRP-mCh-R5-6H is 6mg/L and for 6H-R5-
mCh-HRP is 3mg/L after Ni-purification.  
 
2.4 Extraction of SiO2 from sand 
 
The protocol followed previously published methods 
with some changes [28,29] (Fig. S1). Using small amounts 
of sand (<5g) the sand and crushed NaOH was combined 
and the mixture was transferred into a Pyrex assay tube and 
heated over a flame for 3-5 min. After cooling, water was 
added and it was filtered through filter paper QL100 (Fish-
erbrand). H2SO4 (95% 0.25-1mL) was added carefully, drop 
by drop, to the filtered solution. The white precipitate was 
collected, centrifuged (13k rpm for 1min) and washed with 
water several times (1mL, 3X). The white precipitate was 
dried at room temperature for 5+ days. Original sands and 
dried precipitate were analyzed by FTIR (SpectrumOne, 
Perkin Elmer) and imaged by light microscopy. The surface 
area was calculated by Brunauer-Emmett-Teller (BET) sur-
face area analysis (Quantachrome Instruments), ~100mg 
tested. 
 
2.5 Immobilisation of the R5-proteins on silica particles 
 
A suspension of silica particles (10mg/mL, 5mg in 
0.5mL) was prepared in buffered saline (100mM Na2HPO4, 
150mM NaCl, pH 7.5). The mixture was sonicated for 1h 
(water bath FB15056, Fisher Scientific), and a volume of ei-
ther purified protein (R5-mCh-6H, HRP-mCh-R5-6H) or 
crude lysate (R52-mCh-mSOx-R5-6H) was added. The final 
concentration of the protein was between 0.05-0.5mg/mL. 
After mixing by vortex (VariMix, SciEquip), the suspension 
was rotated (SB1 tube rotator, Stuart Science) for 1h and left 
at room temperature to precipitate. The particles became 
pink and the supernatant colorless. The protein modified sil-
ica was centrifuged at 13k rpm for 5min. The percentage of 
R5-protein immobilized was calculated by measuring the 
fluorescence intensity characteristic of mCherry, i.e. ex/em 
587/607nm (Cary Eclipse Fluorescence Spectrophotometer, 
Varian) of the free protein in supernatant at the beginning 
and end of the immobilization.  
Absorbance (Infinite M200, Tecan) and fluorescence 
readings were taken of both particles and free proteins in so-
lution. The particles were washed several times with water 
and no leaching of the protein from the particles to the solu-
tion was observed, as measured by fluorescence. Confocal 
microscopy images were obtained using Leica TCS SP2 
spectral confocal microscopy. 
A Bradford assay was used to determine the total protein 
immobilization. In brief, 20 µL of supernatant following the 
first spin-down after incubation was added to 100 µL Brad-
ford reagent (Coomassie Brilliant Blue in phosphoric acid) 
in a well plate and absorbance at 595nm was measured with 
a UV spectrophotometer and compared with a standard 
curve made with BSA.  
Elution of the proteins off silica was achieved by incu-
bation in 0.5-1M lysine for 30-120min.  
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2.6 Determination of sarcosine and H2O2 
 
Sarcosine or H2O2 was detected by a combination of 
functional R5 proteins (R52-mCh-mSOx-R5-6H and/or 
HRP-mCh-R5-6H or 6H-R5-mCH-HRP, respectively) and 
the dye Amplex UltraRed (AR) for both free and immobi-
lized protein.  
For the detection of sarcosine in well plates with free 
protein, 10µL of purified R52-mCh-mSOx-R5-6H 
(1.9mg/mL) was added to 0-10µL volumes of sarcosine so-
lution (100µM), 10µL of HRP (0.4mg/mL) and 10µL of 
AR (1 mM). For the detection of H2O2, 40µL of purified 
HRP-mCh-R5-6H (0.12mg/mL) was added to 0-20µL of 
841µM H2O2 and 10µL of AR (1 mM). The final volume 
in each well was adjusted to 100µL with water. The fluo-
rescence was measured, after reaction for 20min at room 
temperature (in the dark), at ex/em 530/582 nm, PMT volt-
age 800V, excitation slit 5nm. Emission slit was 10nm for 
mSOx, 5nm for HRP. The increase in fluorescence inten-
sity of substrate standard (I) with respect to the blank (I0) 
was plotted against the concentration of substrate (sarco-
sine or H2O2). Selectivity and pH effect were evaluated 
with a similar protocol (Supporting information, Experi-
mental). 
For each size and pore class of commercial silica parti-
cles, detection of 10µM sarcosine was compared using the 
Amplex UltraRed assay as described above. The quantity 
of silica added was adjusted based on immobilization effi-
ciency in order to maintain equivalent enzyme concentra-
tion. For experiments comparing particle size and pore size, 
the microcentrifuge tubes were rotated for 40 or 60 
minutes, respectively, before fluorescence was measured.  
Endpoint assays for sarcosine were done in well plates, 
50µL each assay with 50µM Amplex UltraRed, 
0.04mg/mL HRP, 3.75mg Si-R52-mCh-mSOx-R5-6H and 
various final concentrations of sarcosine. 
Trinder’s colorimetric assay was adapted to measure 
specific activity of sarcosine oxidase and specific activity 
for HRP constructs was measured using a colorimetric as-
say with ABTS (Supporting information, Experimental). 
 
2.7 Hourglass biosensor construction and use 
 
Hourglass sensors were produced by laser cutting the 
shape from 2mm thick PMMA and sealing both sides with 
PCR plate seal (Thermo Scientific Adhesive PCR Plate 
Seal). Total volumes were 200/240/320µL for the narrow / 
standard /parallel-sided design respectively (Fig. S6). For 
the detection of sarcosine, R52-mCh-mSox-R5-6H immo-
bilized on silica extracted from sand (4.17 mg/mL silica, 
0.19mg protein per 1mg silica) was mixed with AR (4.17 
µM), HRP (0.016 mg/mL) and sarcosine (0µM (blank), 2, 
4, 6, 8µM)) and loaded into the device. For the detection of 
H2O2, HRP-mCh-R5-6H was immobilized on silica ex-
tracted from sand (2.7mg/mL silica, 0.025mg protein per 
1mg silica) was mixed with AR (10.8µM) and H2O2 (0µM 
(blank), 21, 42, 84, 126 µM)) and loaded into the device.  
All concentrations reported are final concentrations in the 
assay. 
Fig. 1. Schematic illustration of the “gene to device” pathway; 1) Protein 
engineering to obtain R5-mCh-Enz, 2) Bacterial culture growth, 3) Pro-
tein expression, 4) Addition of silica (extracted from sand) to crude lysate, 
5) Protein purification/ immobilization/ stabilization on silica, before and 
after examples in microcentrifuge tubes shown, 6) Isolation of silica-R5-
mCh-Enz, 7) Direct use of the silica-R5-mCh-Enz in biosensor platforms, 
as shown by silica-R52-mCh-mSOx-R5-6H for the detection of sarcosine. 
The silica-R5-mCh-Enz particles can be used in 7a) a classical solution 
based assay or 7b) in a novel hourglass biosensor design. (mCh structure 
2HQ5 and mSOx 3QSE from RCSB Protein Data Bank). 
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The sealed device containing the sarcosine or H2O2 sam-
ple, was inverted for mixing as described in the text, each 
time allowing the particles to settle to the bottom (60s). After 
settling, the device was laid on an FFEI reader (505nm LED 
for excitation and a CCD RGB linear sensor for detection) 
and fluorescence intensity was recorded. The images were 
analyzed for grey scale intensity of the red channel in the 
detection area using ImageJ software. An intensity profile 
was extracted along a central line perpendicular to the base 
and the change in area under the curve (AUC) over time rec-
orded or the average intensity at the endpoint (7min) was 
plotted against concentration. 
 
2.8 Particle Shadowgraphy and PIV analysis 
Particle settling was observed using a shadowgraphy 
technique. For illumination, a 100 W light-emitting diode 
(LED) array with a light diffuser was placed behind the 'de-
vice' and aligned to the camera. The resulting shadow was 
captured by a highspeed camera (Phantom v130) with a 12X 
lens and accessories (Navitar). Videos were captured at 
50fps. Fixtures were designed to hold the device and to al-
low rotation in plane or about a horizontal axis through the 
middle of the device (flip). Devices were filled with 5mg/mL 
extracted silica immobilized with R52-mCh-mSox-R5-6H 
suspended in H2O and sealed. Frames from the video were 
converted to grayscale (rgb2gray) and color inverted 
(imcomplement) using MATLAB. 
Particle image velocimetry (PIV) analysis was per-
formed using PIVLab app in MATLAB, using FFT window 
deformation and four successive passes of pixel area 64, 32, 
16 and 8, with 50% step overlap, for each pair of images. 
Image overlays were done in ImageJ using Z-projections of 
maximum pixel value for grayscale inverted video frames 
imparted into virtual stacks.  
In sedimentation modelling, a density of 2.18g/cm3 was 
used with corresponding Pe numbers, based on the calcu-
lated matching velocities using particle diameter as charac-
teristic length. For Pe, mass diffusivity of glycine was used 
as approximation for sarcosine. 
  
3. Results and Discussion 
3.1 Protein architecture and expression  
 
The rationale explored in this work builds on the use of 
silica as a low cost substrate in a biosensor design. It consid-
ers a protein architecture that will integrate the assay reagent 
enzyme with silica via a silaffin (silica affinity) peptide, 
without additional chemical reagents or immobilization 
steps, but with retention of enzyme activity and increased 
enzyme stability. The enzymatic assay for sarcosine usually 
employs the enzyme sarcosine oxidase (SOx) coupled with 
horseradish peroxidase (HRP).  By designing these reagents 
through recombinant protein technology, additional func-
tionality can be incorporated in the protein that will fit them 
more ideally for a diagnostic platform use. Here, we incor-
porate the fluorescent protein mCherry (mCh) to provide a 
visual marker of protein production and isolation success 
with minimal laboratory infrastructure.  
To demonstrate this protein architecture, we have de-
signed plasmids that incorporate the silaffin (silica affinity) 
peptide (R5)[30] and mCherry (mCh) fluorescent protein to-
gether with monomeric sarcosine oxidase (mSOx).  A con-
struct with mSOx was designed (R52-mCh-mSOx-R5-6H) 
for expression in E.coli (Fig. 1, step 1). The inclusion of 
mCherry in an indicator role is immediately evident during 
the production step: for example, expression of the R52-
mCh-mSOx-R5-6H in E.coli produces a pink culture, show-
ing that protein expression has occurred (5 h, Fig. 1, step 2 
to 3) and the protein is ready for collection (Fig. 2). The in-
Fig. 2. Fluorescence intensity at lem/ex 607/587nm for (blue) induced 
and (orange) un-induced culture over growth period for (a) R55-mCh-6H 
and (c) R52-mCh-mSOx-R5-6H, and corresponding cuvette samples (b 
and d) to show visual change in color.  Expression levels can be checked 
semi-quantitatively against a color card (e). 
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crease in the inbuilt fusion protein fluorescence, as a func-
tion of protein expression after induction, is demonstrated 
for two R5 protein constructs with and without mSOx (R55-
mCh-6H and R52-mCh-mSOx-R5-6H), having slightly dif-
ferent growth curves (Fig. 2). It can also be followed semi-
quantitatively (visual color matching – Fig. 2b and d) or 
checked against a color card (Fig. 2e), depending on availa-
ble resources.  
This combined immobilization and visualization func-
tionality, which would normally be fulfilled through sepa-
rate materials and/or equipment, could reduce production 
steps and facilitate an integrated pathway from raw material 
to end diagnostic.  
 
3.2 Silica integration 
 
Silica is an enormously abundant indigenous material; 
e.g. it is the main component from beach sand and can be 
extracted easily [28,29] (Fig. S1) and used directly without 
size selection (see Fig. 5a for particle size distribution for the 
material used in this work). The FTIR spectra of the silica 
extracted from beach sand show characteristic symmetric 
and asymmetric stretching modes for Si-O-Si (804-805 cm-
1 and 1079-1088 cm-1 respectively) and the asymmetric Si-
OH mode (952-953 cm-1), which overlay with silica gel (Fig. 
S1d).  
Despite this similarity, the N2 gas adsorption/desorption 
isotherms (Fig. 3) suggest that the silica precipitated from 
sand-processing is nonporous or macroporous (>50nm) and 
undergoes a nearly reversible multilayer adsorption (type II 
isotherm).  In contrast the commercial silica gel (60 Å pore 
diameter) demonstrates mesoporous (type IV isotherm) be-
havior, which is typical of monolayer/multilayer adsorption 
followed by capillary condensation in the mesopores. This 
is also consistent with the higher density for sand-silica than 
commercial silica gel (Table 1). Fig. 3c also shows that N2 
adsorption on crude sand is very low (negligible adsorption 
of the R5 protein is also found on crude sand).  
Comparison of Fig. 3b and 3d identifies the effect of R5-
protein adsorption on the silica.  The minor hysteresis seen 
in Fig. 3d shifts to a lower relative pressure consistent with 
decreasing pore diameter.  The characteristic ‘step down’ in 
the desorption curve, closing the hysteresis loop is usually 
associated with pore blocking and percolation effects and the 
lower step down relative pressure would be consistent with 
the protein covering on the silica surface contributing to this 
blocking. These differences are supported by comparison of 
BET surface areas and, in particular, >50% reduction in sur-
face area following protein adsorption (Table 1).   
 
Table 1. Characterization of sand and silica. 
Origin Type Density 
(g/cm3) 
BET 
(m2/g) 
Isotherm 
Type 
Commercial Silica gel 1.87 353±2 IV 
USA Silica extract 2.18 272±5 II 
Sand 2.76 <5 - 
Silica extract -
R52-mCh-
mSOx-R5-6H 
2.18  119±5 II  
Ghana Silica extract 2.02 253±5 II 
Sand 2.65 <5 - 
 
Immobilization of the R5-proteins onto the silica (Fig. 1, 
steps 4 and 5) from crude protein extract results in 30-50% 
uptake of total protein from the crude cell lysate (measured 
by the Bradford total protein assay), but this corresponds to 
85-95% selective uptake of the R5-mCherry fusion proteins 
(Fig. 5b) measured via the inbuilt mCherry fluorescence. 
This is consistent with selective immobilization via the R5 
tag. As the R5-mCherry protein becomes adsorbed, the silica 
turns pink and the supernatant becomes colorless (about 1hr; 
Fig. 1, step 5). SDS-PAGE gel following the process from 
crude lysate to R5-protein on silica (Fig. 4), shows that the 
R5 protein band (R52-mCh-mSOx-R5-6H at 73kDa) almost 
completely disappears from the supernatant in contact with 
the silica, as the silica turns pink.  The identity of the protein 
on the silica was confirmed by elution in non-physiological 
conditions from the silica [31,32] (under physiological con-
ditions, the protein is not released).  The R5 protein bands 
were confirmed in the eluent (Fig. 4). 
General protein adsorption on silica is anticipated due to 
interaction with positively charged residues on the surface 
Fig. 3. N2 isotherms for silicas. (a) commercial silica (b) silica extracted 
from sand (USA) (c) sand (USA) and (d) silica extracted from sand (USA) 
immobilized with R52-mCh-mSOx-R5-6H. 
Fig. 4. Immobilization process from crude lysate as shown by (a) SDS 
page gel for R52-mCh-mSOx-R5-6H, showing in lane (1) crude lysate, 
(2) supernatant after immobilization of silica, (3) eluent off silica and 
(4) eluent from Ni.  Purification pathway shown in (b). The band corre-
sponding with the R52-mCh-mSOx-R5-6H is significantly diminished 
in the supernatant after immobilization on silica and reappears in the 
eluate from the silica, along with a small amount of other proteins. L 
indicates molecular weight ‘Ladder’. The lower molecular weight band 
seen in the purified proteins indicates that the mCherry has undergone 
a partial hydrolysis of its chromophore acylimine bond during SDS-
PAGE analysis. 
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of the protein. This has been shown for the reference mate-
rial SOx-6H, without the R5, included in Fig. 5b. However, 
it can also be seen in this figure that the addition of the R5 
peptide provides a tailored affinity site for silica, thereby in-
corporating a more selective immobilization capability for 
the protein without requiring additional chemical coupling 
reagents. R5 belongs to the proteins rich in arginine and ly-
sine involved in silica precipitation (silaffins [30,33–35]). 
By adding the 19-amino acid R5 sequence 
(SSKKSGSYSGSKGSKRRIL) to mCherry the estimated pI 
for the protein shifts positive by ~1 unit for each R5 peptide 
unit added [36], due to the positively charged residues on the 
R5 polypeptide (K and R) [37]. These will interact with the 
negative charge of the silica surface [38]. The protein ad-
sorption on the surface is expected to be entropically driven 
by the release of water molecules and sodium ions on the 
surface [39–42] . This should increase the affinity of the fu-
sion protein for binding to silica.   
These data raise the interesting question about the con-
tribution of surface area and pore size in the protein immo-
bilization and subsequent available activity of the protein. 
Figure 5b (using saturation concentrations of protein) does 
not suggest any difference in immobilization efficiency be-
tween the silica extracted from sand and the commercial sil-
ica gel. However, selecting discrete size classes shows the 
effect of size on immobilization efficiency (Fig. 5c). As par-
ticle size increases,  immobilization efficiency decreases for 
the same concentration of R52-mCh-mSOx-R5-6H in crude 
lysate (45µg total protein/mg silica). This is expected since 
the surface area to volume ratio decreases with increase in 
particle diameter. Using a theoretical total surface area based 
on the median particle diameter and assuming spherical par-
ticles, the relative decrease in immobilization efficiency fol-
lows closely with the decrease in total surface area (Fig. 5d). 
This suggests that increasing the weight of larger silica for 
the same protein concentration, will increase immobilization 
efficiency (Fig. S2), indicating that protein concentration 
used in Fig. 5c is above saturation for available surface area 
of the larger sized particles of silica used. 
It can also be seen that increasing the average pore size 
of commercial silica gel from 60 Å to 150 Å increases the 
immobilization efficiency for the same particle diameter 
(Fig. 5f). This is in line with the expected size of the proteins, 
as the unit cell of mSOX is reported as 71 x 69.7 x 72.9 Å3 
(PDB 3QSE for crystal structure for the complex of sub-
strate-reduced mSOx with sarcosine); mCh is reported to 
have unit cell of 48.8 x 42.9 x 61 Å3 (PDB 2H5Q for Crystal 
structure of mCh) and the dimension of the native HRP 
(MW: ~ 44 kDa) in a neutral buffer solution was predicted 
to be 62 × 43 × 12 Å3 by a scanning tunneling microscopy 
study [43]. Hence, for commercial silica gels of 60 Å and 
the extracted silicas showing non-porous behavior, immobi-
lization is expected to be largely surface immobilization, 
whereas the 150Å pore silica accepts immobilization into the 
pore and can thus achieve a higher immobilization effi-
ciency.  
Nevertheless, correlation with protein activity also needs 
to be established. Klein et al [44] observed that green fluo-
rescent protein (GFP) shows no significant adsorption to sil-
ica nanoparticles unless it is denatured, which they attribute 
to FPs being highly structured and not susceptible to loss of 
secondary structure. In contrast, red fluorescent proteins 
have been reported to be more susceptible to adsorption on 
silica but are denatured [45]. An initial examination of the 
resultant activity for the R5 immobilized proteins containing 
mCherry can be made from the mCherry fluorescence. Flu-
orescent lifetimes between 1.45-1.68ns were measured for 
all constructs with mCherry (Table S1).  These are compa-
rable with the reported lifetime for mCherry (1.46ns) [46] 
and therefore suggests that secondary structure (and the 
chromophore) is retained. Fig. S3 and Table S2 also shows 
that all the immobilized and solution R5-mCherry constructs 
exhibited nearly identical red fluorescence with excita-
tion/emission peaks at 587/607 nm.    
 
 
 
 
 
 
Fig. 5. Immobilization efficiency and silica type. (a) Particle size (equiva-
lent sphere diameter) distribution of the silica extract as measured by laser 
diffraction and the morphology microscope. (b) Immobilization of the R5-
mCh-proteins on silica gel powder (<63µm, blue) and extracted silica (see 
(a) for size distribution, purple) (5mg), as measured by mCh fluorescence 
(except for SOx-6H - measured by Bradford assay). R52-mCh-mSOx-R5-
6H was direct from lysate (~5mg/mL) while the others were Ni-purified 
protein (R5-mCh-6H 0.05 mg/mL, HRP-mCh-R5-6H 0.1mg/mL). (c) Im-
mobilization efficiency across size fractions of various silica size classes. 
75µL of crude lysate for R52-mCh-mSOx-R5-6H (estimated 6.6mg/mL) 
added to 5mg of each silica type. (d) Total surface area (SA) and immobi-
lization efficiency normalized to silica <63µm. (e) Activity of silica size 
classes for 10µM sarcosine. (f) Immobilization efficiency of silicas of 200-
500µm particle diameter with different average pore diameter and (g) cor-
responding activity in the presence of 10µM sarcosine. 
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3.3 Evaluation of the sílica-R5-enzymes in bioassay 
 
Fig. 6c shows the calibration for sarcosine concentration us-
ing R52-mCh-mSOx-R5-6H in solution with the coupled 
horseradish peroxidase (HRP) reaction (Fig. 6a). R52-mCh-
mSOx-R5-6H, collected on silica from the crude protein ly-
sate and washed (Fig. 1, step 6), can also be used directly for 
the diagnostic, without any further processing (Fig. 6b; Fig. 
S4). In this instance, as discussed above, the immobilization 
efficiency for R52-mCh-mSOx-R5-6H on silica was >90% 
and >95% of the activity remained after 2 months of storage 
at room temperature (Fig. 6e), compared with <20% for the 
protein in solution.  The Km for the silica-R52-mCh-mSOx-
R5-6H (Fig. 1, step 7a; Fig. 6b; Fig. S4) was 16.5±0.9mM 
(compared with 16.5±0.4 mM, 16.3±0.3 mM, and 16.1±0.4 
mM for R52-mCh-mSOx-R5-6H, mSOx-R5-6H and mSOx-
6H respectively in solution), which suggests that there has 
been no conformational impact on the sarcosine binding site 
due to the protein fusion or immobilization. 
Although immobilization efficiency increased with an 
increase in pore diameter (Fig. 5f), the enzymatic activity on 
the 150 Å pore silica is less than the 60 Å pore silica for the 
same mSOx concentration (Fig. 5g). This suggests that de-
spite the higher enzyme immobilization, the active site of the 
enzyme is not as accessible in the pore, or else additional 
interactions between the pore surface and the protein in the 
3D pore space have caused denaturation of the active site. 
We can conclude that for the reaction with sarcosine, pri-
marily surface immobilization is desirable and so no ad-
vantage is gained from pores having dimensions compatible 
with enzyme ingress. 
HRP is widely used in bioassays, either as a label or to 
detect peroxide as co-product. However, recombinant HRP 
is a difficult protein to express, so that many commercially 
available peroxidases remain largely an isoenzyme mixture 
from plant extracts, requiring normal downstream pro-
cessing purification and isolation steps. Recombinant HRP 
has a tendency to form inclusion bodies (IBs) with low yield 
[47] of active protein. However, both HRP-mCh-R5-6H and 
6H-R5-mCh-HRP (type C HRP) have been transformed in 
E.coli NEB Turbo cells and expressed in E.coli Rosetta II 
and pLySs cells, respectively, without IB formation. This is 
possibly the result of the R5 sequence and the change in pI 
of the protein improving its solubility. The protein could 
therefore be isolated from the soluble cell fraction; Kms of 
3.8mM and 1.6mM were measured for 6H-R5-mCh-HRP 
and HRP-mCh-R5-6H, respectively. This is consistent with 
the range of values reported in the literature for different 
HRP isoenzyme preparations [48], compared with a Km of 
8µM for the commercially available mixture of acidic and 
basic isoenzymes (Fig. S8).  The R5-enzyme retained 60-
80% of its activity for more than 2 weeks, even at room tem-
perature (the wild type enzyme lost 90% of its activity in 4 
days, Fig. 6f).  Fig. 6d shows that the response curve for both 
the N and C terminal recombinant proteins are similar and 
thus suggests that the fusion of mCh to HRP has not caused 
loss of enzyme activity.  
Although this enzyme could be isolated directly from the 
cell lysate on silica, it needs folding with heme to activate 
the enzyme. No significant difference was observed in the 
specific activity of HRP-mCh-R5-6H if activation with 
heme occurred before or after the protein was immobilized 
on silica, however, a decrease was observed in the specific 
activity of 6H-R5-mCh-HRP if activation was done after im-
mobilization (Table S3). In addition, the immobilization was 
less efficient when it occurred prior to reactivation, only 
60% of total protein, as compared to >75% total protein im-
mobilized when it followed activation. With heme activation 
prior to immobilization, the heme-folded enzyme gave a 
specific protein immobilization efficiency on silica of >90% 
(Fig. 5b) and was shown to work in tandem with the mSOx-
silica in a sarcosine assay.  
The optimal pH is 7.5 for WT SOx [49] but both the 
crude lysate and the immobilized R52-mCh-mSOx-R5 show 
greater retention of activity in the lower pH range than WT 
SOx (Fig. S5d). In contrast, the reported optimal pH is 6.0-
6.5 for HRP (by supplier). Experimentally, WT HRP 
showed similar activity across the range of 5.0-7.5 (Fig. 
S5b). This broad range of activity is consistent with the mix 
of acidic and basic isozymes that make up the commercial 
enzyme. In comparison, the optimal pH of immobilized 6H-
R5-mCh-HRP (type C HRP) is expected to be at a higher pH 
range; 7.0-8.0 was found in this experiment, which matches 
better with the optimal pH of R52-mCh-mSOx-R5-6H.  
The selectivity of recombinant 6H-R5-mCh-HRP and 
WT HRP was evaluated against dopamine, L-ascorbic acid, 
Fig. 6. Activity and stability of R5-mCh-Enz. (a) Scheme showing signal 
generation from 2-enzyme system combing mSOx and HRP.  Calibration 
curve for (b) R52-mCh-mSOx-R5-6H on silica and for free proteins in so-
lution for (c) R52-mCh-mSOx-R5-6H and (d) HRP constructs, 
λex.530nm/λem.582nm plotted against concentration. The isolated HRP 
showed a linear response to H2O2 in the range 0-200µM, while mSOx is 
linear in the range of 0-10µM. (e) Stability of immobilized R52-mCh-
mSOx-R5-6H as compared to mSOx-6H, as measured by Trinder’s colori-
metric assay. (f) Stability of the wild type HRP and the HRP-mCh-R5-6H 
over 4 weeks at 4°C and ambient temperature, based on ABTS measure-
ments of reaction rate. 
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glucose and uric acid [50], with minimal cross reactivity ob-
served (Fig S5a). The selectivity of recombinant and WT 
SOx was evaluated against glycine, L-proline, N-methyl-L-
alanine, L-alanine, and creatinine [51–53]  (Fig. S5c). Gly-
cine, L-proline, L-alanine and creatinine show minimal 
cross reactivity with either recombinant or WT sarcosine ox-
idase at 10µM. The concentration of alanine and creatinine 
in urine is approximately 1000 fold and 2000 fold higher 
than sarcosine, respectively [54–56], so corresponding final 
concentrations of both were also tested. Less than 5% cross 
reactivity was observed for R52-mCh-mSOx-R5-6H. In con-
trast, N-methyl-L-alanine results in 50-60% relative re-
sponse for R52-mCh-mSOx-R5-6H compared with 10% 
cross reactivity with the WT SOx. It is known that mSOx 
can oxidize other secondary amino acids like , N-methyl-L-
alanine [52].	However, N-methyl-L-alanine is not reported 
as an interferent in urine samples so it is not expected to have 
an effect on sarcosine detection in urine. 
 
3.4 Designing an hourglass biosensor 
 
The previous section shows that the silica-enzyme can be 
directly used in bioassay with improved stability. Classical 
diagnostic platforms have mostly used the immobilized pro-
tein as the stationary phase, where the sample diffuses trans-
versally or laterally into the protein layer. For example, sam-
ple fill into a glucose test strip or lateral flow immunoassays.  
The latter have also employed packed beds of functionalized 
beads similar to the silica-enzymes produced here [57–60].  
However, the silica particle format also allows other biosen-
sor conformations to be explored. Taking inspiration from 
an hourglass (or sand glass), a design can be considered with 
the particles passing through the sample (Fig. 1, step 7b). 
Particle sedimentation is controlled by the internal shape and 
dimensions of the chamber (e.g. parallel, waisted, spiral 
etc.). 
To explore the feasibility of this principle, with an inho-
mogeneous natural sample such as silica obtained from 
beach sand (see size distribution in Fig. 5a), we can compare 
the apparent activity of different sized particles in a dynamic 
mixing system: the relative enzymatic activity for the differ-
ent sized silica particles (Fig. 5e) when suspended in solu-
tion and under rotation, showed the size fraction with the 
smallest particles (<63µm silica gel 60) had a lower response 
in the presence of 10µM sarcosine compared with the size 
classes containing only larger particles (6-35 µm and 40-
63µm, Fig. 5e). Importantly, in this experiment, the larger 
particles cause more turbulent mixing of the solution 
whereas the smallest particles remain largely suspended in 
place, potentially resulting in the creation of local depletion 
zones. We propose therefore that in the hour glass model, 
the reaction will not be limited by the establishment of a de-
pletion zone if the particles are sufficiently large to precipi-
tate through the sample. 
 The influence of the funneling shape on the basic hour-
glass design was considered (Fig. S7) and it was found that 
the positioning of the particles following sedimentation de-
pends on the “waist-dimensions” and axis of inversion of the 
device (“flip” or “tilt”). It is seen that by narrowing the waist 
of the hourglass, the R5-protein modified particles are 
guided to a resting position beneath the central channel, in-
dependent of inversion technique.  This becomes clearer in 
Fig. 7a, where shadowgraphy and particle image veloci-
metry (PIV) map the particles falling in the first 14 s after 
inversion.  
 
Table 2. Calculated and observed parameters for particles.  
 particle  
radius (µm) 1 10 50 100 150 200 
V
el
oc
iti
es
 (m
/s)
 
OBSERVED -- 0.20 x10-3 
1.13 
x10-3 
5.31 
x10-3 
7.02 
x10-3 
10.2 
x10-3 
spherical parti-
cle 
2.57 
x10-6 
2.5 
x10-4 
5.79 
x10-3 
1.96 
x10-2 
3.69 
x10-2 
5.49 
x10-6 
natural  
sediment  
1.91 
x10-6 
1.9 
x10-4 
4.41 
x10-3 
1.49 
x10-2 
2.78 
x10-2 
4.06 
x10-2 
particle  
fraction 0.2 
6.86 
x10-7 
6.82 
x10-5 
1.6 
x10-3 
6.2 
x10-3 
1.26 
x10-2 
1.9 
x10-2 
particle  
fraction 0.3 
3.71 
x10-7 
3.69 
x10-5 
8.82 
x10-4 
3.7 
x10-3 
7.81 
x10-3 
1.23 
x10-2 
Pe
cl
et
 
Pe natural sedi-
ment 
3.47 
x10-3 
3.45 4.01 
x102 
2.71 
x103 
7.58 
x103 
1.48 
x104 
Pe particle frac-
tion 0.2 
1.25 
x10-3 
1.24 1.45 
x102 
1.13 
x103 
3.44 
x103 
6.91 
x103 
 
# Matches between calculated and observed are indicated by shaded 
cells. No observed velocities are reported for particles r <10 µm due to lim-
itations of camera resolution. 
 
Fig. 7. Characterization of particle sedimentation for three basic hour-
glass designs (b(i)) narrow, (b(ii)) waisted and (b(iii)) parallel sided, 
showing sampling points in the middle (orange line) and towards the base 
(blue line). (a) Velocity profiles across the bottom line show particle sed-
imentation position and velocity with particle stream width less than the 
waist of the waisted designs, indicating the flow-focusing effect of eddies 
on either side of the falling particles. (c) Plot of the maximum velocity of 
the particles over time as they cross the indicated lines (middle, bottom). 
Bold lines show 10pts moving average for the middle (orange) and base 
(blue) data, grey shows raw data. (d) colour-inverted stills of particle sed-
imentation for selected time points after flipping. (e) Particle trajectories 
over time.  
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Immediately following inversion, plumes of large parti-
cles or agglomerates entraining smaller particles, with effec-
tive radii in the range of 100-200µm fall with a maximum 
terminal velocity estimated from the PIV data of 1.3 -11.3 x 
10-3 m/s.  The driving buoyancy force behind the plumes is 
the gravity acting on the higher density of the particles tem-
porarily suspended within a fluid, and the sedimentation pat-
terns can be seen visually in Fig. 7d. At these velocities and 
particle size, the Reynolds number (Re) is in the region 0.2-
7.6, outside the region in which Stokes Law applies (Re 
<0.1). For all the designs, the experimental velocity data, 
recorded near the base of the device (blue line, Fig. 7b) are 
lower than expected for a smooth, spherical particle of the 
same diameter, calculated according to the numerical equa-
tion developed by Guo [61], disregarding interactions with 
other particles or the fluid (Table 2). This is anticipated from 
consideration of the irregular shape of natural silica ex-
tracted from sand (Fig. S1) and resulting frictional forces. 
Zhiyao et al [62] proposed a formula that adjusts for the ef-
fect of particle shape, however, this does not fully account 
for the observed decrease in terminal velocity (Table 2). To 
account for this discrepancy, the action of the fluid displace-
ment is considered during sedimentation. Despite an overall 
volume fraction of particles in the device <0.003, the local 
volume fraction of particles in the plumes is much higher. 
Immediately after inversion, hindered settling, from the up-
ward motion of the displaced fluid interacting with the par-
ticle(s) [63], can thus result in lower velocities.  As can be 
seen from Table 2, the experimental data in the initial 
plumes are comparable with an apparent particle fraction of 
0.2-0.4 for the particles falling initially of r >50 µm. Smaller 
less clustered particles falling after the initial plumes, on the 
other hand, show less hindered settling and behave more like 
smaller volume fraction natural sediment.  
The influence of the waist constriction is highlighted in 
Fig. 7c(i-iii), where maximum particle velocity is compared 
in the middle of the device (orange line) and near the base 
(blue line). Although the maximum velocity (but not particle 
position) near the base of the device is nearly independent of 
the design, there is a clear retardation of sedimentation 
within the narrow channel compared with the other designs. 
The straight-sided and wide-waisted hourglasses achieve lit-
tle focusing of the particle sedimentation (Fig. 7a(ii-iii)), 
whereas the narrow hourglass shape (Fig.  7a(i)) leads to the 
central focusing of the particle sedimentation. This defines 
the final position of the particles in an area beneath the cen-
tral tube (irrespective of inversion axis) and creates a repro-
ducible inversion pattern with the particles always starting 
from the same location for each inversion. This is not seen 
in the other designs (Fig. 7b/c(ii-iii)). Since the enzyme 
linked assay is a dynamic reaction process, this reproducible 
sedimentation ensures that a reproducible process occurs 
and thus lends itself to a biosensor platform. 
 
3.5 Hourglass biosensor demonstration 
 
Despite the high volume density of small particles in the 
silica extracted from sand, entrainment in the initial plumes 
with larger particles provides an efficient precipitation of the 
heterogeneous silica. Sampling from the overall trajectory of 
particle settling, as shown in Fig. 7e, predicts that 80-90% 
of the cell volume is ‘sampled’ on each inversion by parti-
cles passing through the cell between 2 - 14s after each in-
version. This provides an indicative efficiency for the de-
sign. Based on their estimated velocities and particle size, 
the Péclet number (Table 2) suggests that particles with radii 
< 10µm would be in a diffusion controlled regime. The 
smallest particles which didn’t become entrained in the 
plumes with Re< 0.1, continue to fall for circa 60s after in-
version in a laminar fashion. 
Fig. 8 demonstrates the hourglass format containing 
HRP-mCh-R5-(6H)-silica or silica-R52-mCh-mSOx-R5-6H 
for peroxide and sarcosine measurement respectively. Fig. 
8a and b show visually that the fluorescence increases in the 
hourglass with concentration of enzyme substrate. To obtain 
a fully quantitative output, the fluorescence intensity was 
measured and the intensity plotted on a trajectory perpendic-
ular to the hourglass base through the central line of the cell. 
The area under this curve (AUC) shows a linear relationship 
with concentration for both hydrogen peroxide and sarcosine 
(Fig. 8c and 8d following 2 inversions).  
However, this is a dynamic process and Fig. 8e follows 
the increase in fluorescence after further inversions reveal-
ing a linear relationship with time, even for 30 inversions 
(=30 min).  This leads to a robust time insensitive quantita-
tive measurement protocol: for example, taking the change 
Fig. 8. Immobilized protein on silica extracted from sand used directly in 
the hourglass for (a) H2O2 (with HRP-mCh-R5-(6H) silica) and (b) sar-
cosine (with silica-R52-mCh-mSOx-R5-6H). Images taken 7min after 
sample addition.  The change in fluorescence, integrating the red channel 
intensity at right angles from the base along the middle line of the hour-
glass over 5min plotted against (c) H2O2 and (d) sarcosine concentration, 
following two inversions of 60s. The different concentration ranges 
measured for these two “silica-enzymes” reflect their different Km. (e) 
Fluorescence increase with device inversions/time 6 µM sarcosine (f) 
Average red channel intensity of the upper and lower chamber of the de-
vice after 6 inversions. (g) Endpoint assay for 50uL sample at 60min 
showing a linear relationship of intensity with [sarcosine] with insert 
showing visual detection of fluorescence in 50µL mini-hourglass at 
60min. (h) Consumption of sarcosine with time, showing completion by 
~40 min. 
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in fluorescence for the same ∆t at any point along that time 
curve in Fig. 8e would produce the same result. Fig. 8f com-
pares the result at 7min (6 inversions), for the top and bottom 
compartments, showing good linearity and reproducibility. 
The detection range (2.5 to 10 µM) for this simple assay for-
mat corresponds to the range required to detect elevated sar-
cosine levels in the urine of prostate cancer patients (> 5 µM 
[25,26]). A trial with prostate cancer patients using this as-
say will be reported elsewhere [64]. 
By contrast, an end-point assay can also be designed that 
uses a smaller sample.  For example, with 50µL total sample, 
consumption is achieved within circa 40 mins (Fig. 8h) pro-
ducing a linear relationship with sarcosine concentration 
(Fig. 8g).  This assay can be extremely sensitive and valua-
ble where only very small samples are available.  For exam-
ple, Fig. 8g insert shows a 50µL hour glass imaged at 60min 
with clear visual distinction between 0, 2 and 10 µM sarco-
sine.  
  
4. Conclusions 
In its study on increasing access to diagnostics in LMICs, 
WHO reports that diagnostic tests are not affordable in these 
vulnerable countries, where the burden of disease is highest 
[65]. The absence of affordable medical diagnostics under-
mines the cornerstones of effective clinical decision-making 
[66]. Clinicians often don’t have enough information, so 
syndromic or presumptive treatment is particularly common.  
Lack of diagnostics leading to unnecessary or inappropriate 
use of antibiotics is one of the outcomes and has been cited 
as the “Achilles Heel” in combating antimicrobial resistance 
[67,68].  
Makerere has suggested that there is a need to empower 
local people with improved healthcare knowledge and ser-
vices [69,70] and a workshop held during the Geneva Health 
Forum 2016 considered how to increase access to quality di-
agnostics in LMICs using social innovation [71], centering 
production around local communities, with a target of mini-
mal cost per patient, to improve patient outcome [72]. How-
ever, even basic raw materials to achieve this vision have to 
be imported at too high a cost due to a complex manufactur-
ing and distribution chain [73] without global Purchasing 
Power Parity (PPP). This prohibits uptake in low income 
countries [74], so the development of local enterprises and 
infrastructure is not competitive. Often the local product, 
even when marketed at an unsustainable small margin, 
would still be more expensive than the imported finished 
(unaffordable) product [75]. 
In this viscous circle, in vitro diagnostics that are availa-
ble in low income countries are often the result of interna-
tional donors supporting disease-specific initiatives. The 
enormous value of these initiatives is seen for example, in 
HIV and malaria testing [6], but tests need to become self-
sustaining [68], without charitable donor commitment. Fur-
thermore, even in relatively well supported urban laborato-
ries that have been equipped by donor and NGO investment, 
instrumentation sits idle since reagent and kit costs have ren-
dered it beyond budget [76].  
The research reported herein has taken the first step to 
integrate the protein design for a diagnostic and reduce 
downstream processing and the use of chemical coupling re-
agents. It has demonstrated a protein design that employs an 
affinity binding sequence for silica in fusion with the central 
assay reagent protein (SOx, HRP) targeting the analyte. It 
was shown that the production could be followed easily 
without major infrastructure resources, by incorporation of 
a colored protein in the fusion construct design.  This could 
be used for production control and monitoring of subsequent 
activity of protein in storage. 
Using silica/sand as a protein carrier also provides a 
means of easy protein collection by adsorption and silica-
precipitation (cf magnetic particles [19,77,78]), and presen-
tation of a versatile protein-silica preparation for many clas-
sical bioassay formats and microfluidics, as well as more in-
novative designs (Fig. 1, step 7b). Depending on the choice 
of functional enzyme, the silica-R5-protein constructs can 
be used for either small molecule detection, immunoassay or 
nucleic acid amplification, e.g. polymerases like Taq and 
Bst. The wide availability of sand worldwide, provides a 
low-cost substrate acting both as carrier and stabilizer for the 
protein (in comparison to the soluble protein, the ‘sand-en-
zymes’ were seen to be stable for weeks at room temperature 
(22oC)), as well as reducing the complexity of the isolation 
and purification process. We have demonstrated a prelimi-
nary example of the “gene to diagnostic” pathway, high-
lighting the use of silica as a protein carrier for SOx. A novel 
biosensor platform was conceived inspired by an hourglass.  
Using PIV, the sedimentation pattern was studied and an 
hourglass with narrow waist shown to give the best control 
of particle trajectory.  This was demonstrated for sarcosine 
measurement and sarcosine determination shown in the clin-
ically useful range in urine for prostate cancer [25,26]. Re-
sults from the study of the device used with urine samples 
from patients with prostate cancer will be reported shortly 
[64]. 
Since affinity peptides have been identified for an in-
creasing range of substrates [79] including materials like cel-
lulose and lignin, this approach has broad applicability to 
abundant naturally occurring materials. Such molecular and 
synthetic biology tools [80,81] may help reduce hurdles to 
local production in LMICs. Furthermore, decentralized pro-
duction with a low carbon footprint is increasingly important 
globally and taking a holistic approach to an integrated di-
agnostic design may be more flexible for different needs 
worldwide.  
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